Impairment of the collagenase-3 endocytotic receptor system in cells from patients with osteoarthritis

Osteoarthritis and Cartilage

Volumn 11, Issue 12, 2003, Pages 854-863

  Walling, H W ^a,g   Raggatt, L J ^b   Irvine, D W ^c   Barmina, O Y ^a   Toledano, J E ^c   Goldring, M B ^d   Hruska, K A ^e   Adkisson, H D ^e   Burdge, R E ^c   Gatt Jr , C J ^f   Harwood, D A ^f   Partridge, Nicola C ^a,b,c  

^a SAINT LOUIS UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e BARNES JEWISH HOSPITAL   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; CELL RECEPTOR; COLLAGEN TYPE 2; COLLAGENASE 3; IODINE 125; LIGAND; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN ASSOCIATED PROTEIN; MATRIX METALLOPROTEINASE; MESSENGER RNA;

ADULT; AGED; ARTICLE; AUTOPSY; BONE MATRIX; CARTILAGE CELL; CELL CULTURE; CELL SURFACE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG TARGETING; ENDOCYTOSIS; ENZYME ANALYSIS; ENZYME BINDING; ENZYME DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; EXTRACELLULAR SPACE; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; INTERNALIZATION; KNEE ARTHROPLASTY; KNEE OSTEOARTHRITIS; MALE; OSTEOBLAST; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIOCYTE;

EID: 10744230554     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1063-4584(03)00170-5     Document Type: Article

References (61)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41:1343-55.
3. Hannan MT, Anderson JJ, Zhang Y, Levy D, Felson DT. Bone mineral density and knee osteoarthritis in elderly men and women. The Framingham study. Arthritis Rheum 1993;36:1671-80.
4. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis. Arthritis Rheum 1995;38:1535-40.
5. McAnulty RJ, Laurent GJ. In vivo measurement of collagen metabolism in cartilage and bone. In: Maroudas A, Kuettner K, Eds. Methods in Cartilage Research. San Diego: Academic Press 1993;140-2.
6. Poole AR. Cartilage in health and disease. In: McCarthy DJ, Coopman WJ, Eds. Arthritis and Allied Conditions: A Textbook of Rheumatology. Philadelphia: Lea and Febiger 1997;255-308.
7. Hollander AP, Heathfield TF, Webber C., et al. Damage to type II collagen in aging and osteoarthritis starts at the articular site, originates around chondrocytes, and extends into the cartilage with progressive degeneration. J Clin Invest 1995;96:2859-69.
8. Lohmander LS. The release of aggrecan fragments into synovial fluid after joint surgery and in osteoarthritis. J Rheumatol 1995;22(Suppl 43):75-7.
9. Shingleton WD, Hodges DJ, Brick P, Cawston TE. Collagenase: a key enzyme in collagen turnover. Biochem Cell Biol 1996;74:759-75.
10. Aigner T, Vornehm SI, Zeiler G, Dudhia J, von der Mark K, Bayliss MT. Suppression of cartilage matrix gene expression in upper zone chondrocytes of osteoarthritic cartilage. Arthritis Rheum 1997;40:562-9.
11. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998;10:602-8.
12. Pelletier JP, Martel-Pelletier J, Howell DS, Ghandur-Mnnaymneh L, Enis JE, Woessner JF Jr. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 1983;26:63-8.
13. Kozaci LD, Buttle DJ, Hollander AP. Degradation of type II collagen, but not proteoglycan, correlates with matrix metalloproteinase activity in cartilage explant cultures. Arthritis Rheum 1997;40:164-74.
14. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
15. Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993;36:372-9.
16. Ishiguro N, Ito T, Ito H, Iwata H, Jugessur H, Ionescu M, et al. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum 1999;42:129-36.
17. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59:455-61.
18. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989;84:678-85.
19. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier J-M, Pelletier JP. Excess of metalloproteinases over tissue inhibitors of metalloproteinases may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994;70:807-15.
20. Fosang AJ, Last K, Knauper V, Murphy G, Neame PJ. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett 1996;380:7-20.
21. Welgus HG, Jeffrey JJ, Stricklin GP, Eisen AZ. The gelatinolytic activity of human skin fibroblast collagenase. J Biol Chem 1982;257:11534-9.
22. Krane SM, Byrne MH, Lemaitre V, et al. Different collagenase gene products have different roles in degradation of type I collagen. J Biol Chem 1996;271:28509-15.
23. Lemaitre V, Jungbluth A, Eeckhout Y. The recombinant catalytic domain of mouse collagenase-3 depolymerizes type I collagen by cleaving its aminotelopeptides. Biochem Biophys Res Commun 1997;230:202-5.
24. Mitchell PG, Magna HA, Reeves LM, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996;97:761-8.
25. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J Clin Invest 1996;97:2011-9.
26. Shlopov BV, Lie WR, Mainardi CL, Cole AA, Chubinskaya S, Hasty KA. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum 1997;40:2065-74.
27. Billinghurst RC, Dahlberg L, Ionescu M, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45.
28. Dahlberg L, Billinghurst RC, Manner P, et al. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum 2000;43:673-82.
29. Neuhold LA, Killar L, Zhao W, et al. Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin Invest 2001;107:35-44.
30. Murphy G, Stanton H, Cowell S, et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999;107:38-44.
31. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981;195:159-65.
32. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA) structure, control of expression and biological functions. Pharmacol Ther 1993;59:329-41.
33. Omura TH, Noguchi A, Johanns CA, Jeffrey JJ, Partridge NC. Identification of a specific receptor for interstitial collagenase on osteoblastic cells. J Biol Chem 1994;269:24994-8.
34. Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley KMK. Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 1998;41:1639-44.
35. Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Arthritis Rheum 2001;44:585-94.
36. Wu W, Billinghurst RC, Pidoux I, et al. Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis Rheum 2002;46:2087-94.
37. Poole AR, Kobayashi M, Yasuda T, et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis 2002;61(Suppl 2):ii78-81.
38. Walling HW, Chan PT, Omura TH, et al. Regulation of the collagenase-3 receptor and its role in intracellular ligand processing in rat osteoblastic cells. J Cell Physiol 1998;177:563-74.
39. Barmina OY, Walling HW, Fiacco GJ, et al. Collagenase-3 binds to a specific receptor and requires the LDL-receptor related protein for internalization. J Biol Chem 1999;274:30087-93.
40. Forrest SM, Ng KW, Findlay DM, et al. Characterization of an osteoblast-like clonal cell line which responds to both parathyroid hormone and calcitonin. Calcif Tissue Int 1985;37:51-6.
41. Roswit WP, Halme J, Jeffrey JJ. Purification and properties of rat uterine procollagenase. Arch Biochem Biophys 1983;225:285-95.
42. Dodge GR, Diaz A, Sanz-Rodriguez C, Reginato AM, Jimenez SA. Effects of interleukin-γ and tumor necrosis factor α on the expression of the genes encoding aggrecan, biglycan, and decorin core proteins in cultured human chondrocytes. Arthritis Rheum 1998;41:274-83.
43. Freije JM, Diez-Itza I, Balbin M, et al. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem 1994;269:16766-73.
44. Zhang Y, Gray RD. Characterization of folded, intermediate, and unfolded states of recombinant human interstitial collagenase. J Biol Chem 1996;271:8015-21.
45. 131I-labeled human growth hormone of high specific radioactivity. Biochem J 1963;89:114-23.
46. Herz J, Goldstein JL, Strickland DK, Ho YK, Brown MS. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/α2-macroglobulin receptor. J Biol Chem 1991;266:21232-8.
47. Imai S, Konttinen YT, Jumppanen M, et al. High levels of expression of collagenase-3 (MMP-13) in pathological conditions associated with a foreign body reaction. J Bone Joint Surg Br 1998;80B:701-10.
48. Labhard ME, Hollister DW. Segmental amplification of the entire helical and telopeptide regions of the cDNA for human α1(I) collagen. Matrix 1990;10:124-30.
49. Dharmavaram RM, Baldwin CT, Reginato AM, Jimenez SA. Amplification of cDNAs for human cartilage-specific types II, IX, and XI collagens from chondrocytes and Epstein-Barr virus-transformed lymphocytes. Matrix 1993;13:125-33.
50. Davis BA, Sipe B, Gershan LA, et al. Collagenase and tissue plasminogen activator in developing rat calvariae: normal progression despite fetal exposure to microgravity. Calcif Tissue Int 1998;64:416-22.
51. Zlabinger GJ, Menzel JE, Steffen C. Change in collagen synthesis of human chondrocyte culture. I. Development of a human model, demonstration of collagen type conversion by immunofluorescence. Rheumatol Int 1986;6:63-8.
52. Willnow TE, Rohlmann A, Horton J, et al. RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytotic receptors. EMBO J 1996;15:2632-9.
53. Poole AR. Can serum biomarker assays measure the progression of cartilage degeneration in osteoarthritis? Arthritis Rheum 2002;46:2549-52.
54. Lapadula G, Iannone F, Zuccaro C, et al. Integrin expression on chondrocytes: correlations with the degree of cartilage damage in human osteoarthritis. Clin Exp Rheumatol 1998;15:247-54.
55. Durr J, Goodman S, Potocnik A, von der Mark H, van der Mark K. Localization of β1 integrins in human cartilage and their role in chondrocyte adhesion to collagen and fibronectin. Exp Cell Res 1993;207:235-44.
56. Arner EC, Tortorella MD. Signal transduction through chondrocyte integrin receptors induces matrix metalloproteinase synthesis and synergizes with interleukin-1. Arthritis Rheum 1995;38:1304-14.
57. Huhtala P, Humphries MJ, McCarthy JB, Tremble PM, Werb Z, Damsky CH. Cooperative signaling by α5β1 and α4β1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol 1995;129:867.
58. Loeser RF, Carlson CS, McGee MP. Expression of beta 1 integrins by cultured articular chondrocytes and in osteoarthritic cartilage. Exp Cell Res 1995;217:248-57.
59. Chu CR, Dounchis JS, Yoshioka M, Sah RL, Coutts RD, Amiel D. Osteochondral repair using perichondral cells: a one-year study in rabbits. Clin Orthop 1997;340:220-9.
60. Doherty PJ, Zhang H, Tremblay L, Manolopoulos V, Marshall KW. Resurfacing of articular cartilage explants with genetically-modified human chondrocytes in vitro. Osteoarthritis Cartilage 1998;6:153-9.
61. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations in the post-trial era. Nat Rev Cancer 2002;2:657-72.